226,238 Shares in Thermo Fisher Scientific Inc. $TMO Bought by Freestone Grove Partners LP

Freestone Grove Partners LP purchased a new stake in Thermo Fisher Scientific Inc. (NYSE:TMO) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 226,238 shares of the medical research company’s stock, valued at approximately $113,427,000. Thermo Fisher Scientific comprises approximately 0.7% of Freestone Grove Partners LP’s investment portfolio, making the stock its 20th biggest position. Freestone Grove Partners LP owned 0.06% of Thermo Fisher Scientific at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of the stock. Caisse de depot et placement du Quebec acquired a new stake in Thermo Fisher Scientific during the second quarter worth about $105,280,000. Sculptor Capital LP purchased a new stake in Thermo Fisher Scientific in the 2nd quarter worth approximately $20,556,000. Man Group plc acquired a new stake in shares of Thermo Fisher Scientific during the 2nd quarter worth approximately $97,845,000. Western Wealth Management LLC acquired a new stake in shares of Thermo Fisher Scientific during the 2nd quarter worth approximately $654,000. Finally, First Bancorp Inc ME purchased a new position in shares of Thermo Fisher Scientific during the 2nd quarter valued at approximately $48,000. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Stock Performance

NYSE:TMO opened at $634.48 on Thursday. The company has a debt-to-equity ratio of 0.74, a quick ratio of 1.18 and a current ratio of 1.55. The stock has a market capitalization of $234.60 billion, a PE ratio of 34.13, a P/E/G ratio of 2.56 and a beta of 0.85. Thermo Fisher Scientific Inc. has a fifty-two week low of $435.27 and a fifty-two week high of $647.00. The company has a fifty day moving average of $552.22 and a two-hundred day moving average of $510.70.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.71 by $0.32. The business had revenue of $11.99 billion for the quarter, compared to analyst estimates of $11.71 billion. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The company’s revenue for the quarter was up 10.5% compared to the same quarter last year. During the same quarter last year, the business earned $4.28 earnings per share. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. As a group, research analysts forecast that Thermo Fisher Scientific Inc. will post 25.12 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, October 15th. Shareholders of record on Tuesday, September 15th will be paid a dividend of $0.47 per share. This represents a $1.88 annualized dividend and a yield of 0.3%. The ex-dividend date is Tuesday, September 15th. Thermo Fisher Scientific’s payout ratio is 10.11%.

Analyst Ratings Changes

A number of analysts recently issued reports on TMO shares. Wolfe Research began coverage on shares of Thermo Fisher Scientific in a report on Tuesday, June 2nd. They set an “outperform” rating and a $535.00 price target on the stock. KeyCorp reiterated an “overweight” rating on shares of Thermo Fisher Scientific in a research report on Tuesday, May 26th. Morgan Stanley increased their target price on shares of Thermo Fisher Scientific from $620.00 to $650.00 and gave the stock an “overweight” rating in a research note on Friday, July 24th. Piper Sandler lifted their price target on Thermo Fisher Scientific from $510.00 to $600.00 and gave the company a “neutral” rating in a research note on Monday, July 27th. Finally, Wall Street Zen raised Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a report on Saturday, August 1st. One investment analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $619.41.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 20th. The stock was sold at an average price of $629.27, for a total value of $6,292,700.00. Following the transaction, the chief executive officer owned 123,925 shares in the company, valued at $77,982,284.75. This trade represents a 7.47% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael D. Shafer sold 25,500 shares of Thermo Fisher Scientific stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $600.00, for a total value of $15,300,000.00. Following the completion of the sale, the executive vice president directly owned 20,994 shares in the company, valued at $12,596,400. This represents a 54.85% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 73,768 shares of company stock valued at $44,122,820. 0.33% of the stock is owned by insiders.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.